RESUMEN
OBJECTIVE: To determine the effects of exergaming (EXE) on quality of life (QOL), motor, and clinical symptoms in multiple sclerosis (MS). We compared the effects of EXE, balance (BAL), cycling (CYC), proprioceptive neuromuscular facilitation (PNF), and a standard care wait-listed control group on clinical and motor symptoms and quality of life (QOL) in people with MS (PwMS) and determined the effects of subsequent maintenance programs for 2 years in a hospital setting. DESIGN: A randomized controlled trial, using before-after test design. SETTING: University hospital setting. PARTICIPANTS: Of 82 outpatients with MS, 70 were randomized (N=70), and 68 completed the study. INTERVENTIONS: The initial high-intensity and high-frequency interventions consisted of 25 one-hour sessions over 5 weeks. After the 5-week-long initial intervention, the 2-year-long maintenance programs followed, consisting of 3 sessions per week, each for 1 hour. MAIN OUTCOME MEASURES: The primary outcome: Multiple Sclerosis Impact Scale (MSIS-29). SECONDARY OUTCOMES: Measures 5 aspects of health-related QOL (EuroQol 5-Dimension questionnaire), Beck Depression Inventory, 6-minute walk test (6MWT), Berg Balance Scale (BBS), Tinetti Assessment Tool (TAT), and static BAL (center of pressure). RESULTS: MSIS-29 improved most in EXE (11 points), BAL (6), and CYC (6) (all P<.05). QOL improved most in EXE (3 points), CYC, and BAL (2) (all P<.05). TAT and BBS improved significantly (P<.05) but similarly (P>.05) in EXE, BAL, and CYC. 6MWT improved most in EXE (57m), BAL (32m), and CYC (19m) (all P<.001). Standing sway did not change. Maintenance programs further increased the initial exercise-induced gains, robustly in EXE. CONCLUSIONS: A total of 25 sessions of EXE, BAL, CYC, and PNF, in this order, improved clinical and motor symptoms and QOL, and subsequent 2-year-long thrice weekly maintenance programs further slowed symptom worsening and improved QOL. EXE was the most and PNF was the least effective to improve clinical symptoms, motor function, and QOL in PwMS.
Asunto(s)
Esclerosis Múltiple , Ejercicios de Estiramiento Muscular , Terapia por Ejercicio/métodos , Humanos , Equilibrio Postural , Calidad de Vida , Encuestas y CuestionariosRESUMEN
Endocrine Disrupting Chemicals (EDCs) are man-made compounds that alter functions of the endocrine system. Environmental mixtures of EDCs might have adverse effects on human health, even though their individual concentrations are below regulatory levels of concerns. However, studies identifying and experimentally testing adverse effects of real-life mixtures are scarce. In this study, we aimed at evaluating an epidemiologically identified EDC mixture in an experimental setting to delineate its cellular and epigenetic effects. The mixture was established using data from the Swedish Environmental Longitudinal Mother and child Asthma and allergy (SELMA) study where it was associated with lower birth weight, an early marker for prenatal metabolic programming. This mixture was then tested for its ability to change metabolic programming of human mesenchymal stem cells. In these cells, we assessed if the mixture induced adipogenesis and genome-wide DNA methylation changes. The mixture increased lipid droplet accumulation already at concentrations corresponding to levels measured in the pregnant women of the SELMA study. Furthermore, we identified differentially methylated regions in genes important for adipogenesis and thermogenesis. This study shows that a mixture reflecting human real-life exposure can induce molecular and cellular changes during development that could underlie adverse outcomes.
Asunto(s)
Adipogénesis/efectos de los fármacos , Peso al Nacer/efectos de los fármacos , Metilación de ADN/efectos de los fármacos , Disruptores Endocrinos/efectos adversos , Células Madre Mesenquimatosas/efectos de los fármacos , Asma/etiología , Células Cultivadas , Contaminantes Ambientales/efectos adversos , Epigenómica/métodos , Femenino , Humanos , Hipersensibilidad/etiología , Masculino , Exposición Materna/efectos adversos , Embarazo , Mujeres Embarazadas , Efectos Tardíos de la Exposición Prenatal/etiología , Suecia , Termogénesis/efectos de los fármacosRESUMEN
We consider the motion of two point masses along a vertical half-line that are subject to constant gravitational force and collide elastically with each other and the floor. This model was introduced by Wojtkowski who established hyperbolicity and ergodicity in case the lower ball is heavier. Here, we investigate the dynamics in discrete time and prove that, for an open set of the external parameter (the relative mass of the lower ball), the system mixes polynomially-modulo logarithmic factors, correlations decay as O(1/n(2))-and satisfies the Central Limit Theorem.
RESUMEN
Convergent evidence associates exposure to endocrine disrupting chemicals (EDCs) with major human diseases, even at regulation-compliant concentrations. This might be because humans are exposed to EDC mixtures, whereas chemical regulation is based on a risk assessment of individual compounds. Here, we developed a mixture-centered risk assessment strategy that integrates epidemiological and experimental evidence. We identified that exposure to an EDC mixture in early pregnancy is associated with language delay in offspring. At human-relevant concentrations, this mixture disrupted hormone-regulated and disease-relevant regulatory networks in human brain organoids and in the model organisms Xenopus leavis and Danio rerio, as well as behavioral responses. Reinterrogating epidemiological data, we found that up to 54% of the children had prenatal exposures above experimentally derived levels of concern, reaching, for the upper decile compared with the lowest decile of exposure, a 3.3 times higher risk of language delay.
Asunto(s)
Disruptores Endocrinos/toxicidad , Trastornos del Desarrollo del Lenguaje/epidemiología , Trastornos del Neurodesarrollo/epidemiología , Efectos Tardíos de la Exposición Prenatal , Transcriptoma/efectos de los fármacos , Animales , Trastorno del Espectro Autista/epidemiología , Trastorno del Espectro Autista/genética , Encéfalo/efectos de los fármacos , Encéfalo/embriología , Preescolar , Estrógenos/metabolismo , Femenino , Fluorocarburos/análisis , Fluorocarburos/toxicidad , Perfilación de la Expresión Génica , Regulación de la Expresión Génica , Ontología de Genes , Humanos , Locomoción/efectos de los fármacos , Células-Madre Neurales/efectos de los fármacos , Trastornos del Neurodesarrollo/genética , Organoides , Fenoles/análisis , Fenoles/toxicidad , Ácidos Ftálicos/análisis , Ácidos Ftálicos/toxicidad , Embarazo , Medición de Riesgo , Hormonas Tiroideas/metabolismo , Xenopus laevis , Pez CebraRESUMEN
Introduction: There are scant data to demonstrate that the long-term non-pharmaceutical interventions can slow the progression of motor and non-motor symptoms and lower drug dose in Parkinson's disease (PD). Methods: After randomization, the Exercise-only (E, n = 19) group completed an initial 3-week-long, 15-session supervised, high-intensity sensorimotor agility exercise program designed to improve the postural stability. The Exercise + Maintenance (E + M, n = 22) group completed the 3-week program and continued the same program three times per week for 6 years. The no exercise and no maintenance control (C, n = 26) group continued habitual living. In each patient, 11 outcomes were measured before and after the 3-week initial exercise program and then, at 3, 6, 12, 18, 24, 36, 48, 60, and 72 months. Results: The longitudinal linear mixed effects modeling of each variable was fitted with maximum likelihood estimation and adjusted for baseline and covariates. The exercise program strongly improved the primary outcome, Motor Experiences of Daily Living, by ~7 points and all secondary outcomes [body mass index (BMI), disease and no disease-specific quality of life, depression, mobility, and standing balance]. In E group, the detraining effects lasted up to 12 months. E+M group further improved the initial exercise-induced gains up to 3 months and the gains were sustained until year 6. In C group, the symptoms worsened steadily. By year 6, levodopa (L-dopa) equivalents increased in all the groups but least in E + M group. Conclusion: A short-term, high-intensity sensorimotor agility exercise program improved the PD symptoms up to a year during detraining but the subsequent 6-year maintenance program was needed to further increase or sustain the initial improvements in the symptoms, quality of life, and drug dose.
RESUMEN
The development of selective protein kinase inhibitors has become an important area of drug discovery for the treatment of different diseases. We report the synthesis and characterization of a series of novel quinazoline derivatives against three therapeutically important and pharmacologically related kinases: 1) epidermal growth factor receptor (EGFR; wild type and mutant) in the field of cancer, 2) receptor-interacting caspase-like apoptosis-regulatory kinase (RICK) in the field of inflammation, and 3) pUL97 of human cytomegalovirus (HCMV). For reference purpose we have synthesized the four clinically relevant quinazolines, including the lead compounds, which we previously identified for RICK and pUL97. A total of 52 quinazoline derivatives were synthesized and tested on the basis of these leads to specifically target the hydrophobic pocket of the ATP-binding site. Selected compounds were tested on wild-type and mutant forms of EGFR, RICK, and pUL97 kinases; their logP and logS values for assessing suitability as drugs were calculated and hit or lead compounds identified.
Asunto(s)
Receptores ErbB/antagonistas & inhibidores , Inhibidores de Proteínas Quinasas/farmacología , Quinazolinas/farmacología , Proteína Serina-Treonina Quinasa 2 de Interacción con Receptor/antagonistas & inhibidores , Proteínas Virales/metabolismo , Citomegalovirus , Receptores ErbB/genética , Receptores ErbB/metabolismo , Humanos , Proteínas Mutantes/antagonistas & inhibidores , Fosfotransferasas (Aceptor de Grupo Alcohol)/antagonistas & inhibidores , Inhibidores de Proteínas Quinasas/síntesis química , Inhibidores de Proteínas Quinasas/química , Inhibidores de Proteínas Quinasas/metabolismo , Quinazolinas/síntesis química , Quinazolinas/química , Quinazolinas/metabolismo , Proteína Serina-Treonina Quinasa 2 de Interacción con Receptor/genética , Proteína Serina-Treonina Quinasa 2 de Interacción con Receptor/metabolismo , Proteínas Virales/antagonistas & inhibidores , Proteínas Virales/efectos de los fármacosRESUMEN
Although arsenic contamination in the three countries described herein differs, a number of common themes emerge. In each country, the presence of arsenic is both long term and of geological origin. Moreover, in each of these countries, arsenic was only recently discovered to be a potential public health problem, having been first formally recognized in the 1980s or 1990s. In Bangledesh, exposure of the public to arsenic arose as a result of the search for microbially safe drinking water; this search resulted in the sinking of tube wells into aquifers. In Hungary, the natural bedrock geology was responsible for contamination of aquifer water. The genesis of arsenic contamination in Thailand arose primarily from small-scale alluvial mining activities, which mobilized geologically bound arsenic. Because of the complex chemistry of arsenic, and variability in where it is found and how it is bound, multiple mitigation methods must be considered for mitigating episodes of environmental contamination. The Ron Phibun region of Thailand has a 100-yr history of tin mining. A geological survey of the region was conducted in the mid-1990s by the Department of Mineral Resources and Department of Industry of Thailand, and was supported by the British Geological Society. Skin cancer in Thailand was first reported in 1987, in the southern part of the country; among other symptoms observed, there was evidence of IQ diminutions among the population. Arsenic water levels to 9,000 pg/L were reported; such levels are substantially above any guideline levels. A long-term plan to mitigate arsenic contamination was devised in 1998-2000. The plan involved removal of arsenic-contaminated land and improved management of mining wastes. However, at $22 million, the cost was deemed prohibitive for the regional Thai economy. An alternative solution of providing pipeline drinking water to the exposed population was also unsuccessful, either because arsenic contamination levels did not fall sufficiently, or because the quantity of water delivered to the population was inadequate. Membrane technology treatment, using reverse osmosis, was successful during the summer months, but membrane filter replacement costs prevented wide implementation. Less expensive options, such as the use of rainwater jars, were feasible in areas with adequate rainfall. Algae and phytoremediation and wetland treatment of surface waters were useful, but the waste disposal necessitated by such treatments reduces acceptance. The development and population growth in Bangladesh from 1980 to 2000 resulted in improved water quality, primarily because of the drilling of about 10 million tube wells. The unintended consequence of this action resulted in exposure of about 40 million people to toxic levels of arsenic, which was a natural contaminant of the aquifers. Numerous remediation strategies have been implemented to deal with this problem, including the use of dug wells, pond sand filters, household filters, rainwater harvesting, deep tube wells, chemical-based options, and construction of village piped water supplies. Varying levels of success, which is largely dependent on local resources and conditions, have been reported for the different mitigation methodologies. Although Hungary has already invested huge sums of money to reduce arsenic levels in the most contaminated counties, further investments are needed to comply with the strict European threshold value. The fact that arsenic contamination is a natural ongoing process creates a barrier to long-term success. At present, the most appropriate option for securing safe water for drinking and cooking is treatment of water at the tap. Both adsorption and membrane filtration are efficient methods to remove arsenic from drinking water. The presence of contaminants other than arsenic may also require dual or multiple removal processes. Decision makers, as is common, must consider not only removal efficiency but also operating and investment costs of an operation.
Asunto(s)
Arsénico/análisis , Contaminación del Agua/análisis , Arsénico/efectos adversos , Bangladesh , Humanos , Hungría , Tailandia , Contaminación del Agua/efectos adversos , Abastecimiento de Agua/análisisRESUMEN
PURPOSE: Transforming growth factor beta 1 (TGF-ß1) is a cytokine involved in a variety of processes, such as differentiation of fibroblasts into myofibroblasts. TGF-ß1 has also been shown to delay the internalization of the neurokinin-1 receptor (NK-1 R) after its activation by its ligand, the neuropeptide substance P (SP). NK-1 R comprises two naturally occurring variants, a full-length and a truncated form, triggering different cellular responses. SP has been shown to affect important events in the cornea - such as stimulating epithelial cell proliferation - processes that are involved in corneal wound healing and thus in maintaining the transparency of the corneal stroma. An impaired signaling through NK-1 R could thus impact the visual quality. We hypothesize that TGF-ß1 modulates the expression pattern of NK-1 R in human corneal stroma cells, keratocytes. The purpose of this study was to test that hypothesis. METHODS: Cultures of primary keratocytes were set up with cells derived from healthy human corneas, obtained from donated transplantation graft leftovers, and characterized by immunocytochemistry and Western blot. Immunocytochemistry for TGF-ß receptors and NK-1 R was performed. Gene expression was assessed with real-time polymerase chain reaction (qPCR). RESULTS: Expression of TGF-ß receptors was confirmed in keratocytes in vitro. Treating the cells with TGF-ß1 significantly reduced the gene expression of NK-1 R. Furthermore, immunocytochemistry for NK-1 R demonstrated that it is specifically the expression of the full-length isotype of the receptor that is reduced after treatment with TGF-ß1, which was also confirmed with qPCR using a specific probe for the full-length receptor. CONCLUSIONS: TGF-ß1 down-regulates the gene expression of the full-length variant of NK-1 R in human keratocytes, which might impact its signaling pathway and thus explain the known delay in internalization after activation by SP seen with TGF-ß1 treatment.
Asunto(s)
Queratocitos de la Córnea/metabolismo , Regulación de la Expresión Génica , ARN/genética , Receptores de Neuroquinina-1/genética , Factor de Crecimiento Transformador beta1/genética , Adulto , Anciano , Anciano de 80 o más Años , Western Blotting , Diferenciación Celular , Proliferación Celular , Células Cultivadas , Queratocitos de la Córnea/citología , Femenino , Humanos , Inmunohistoquímica , Masculino , Persona de Mediana Edad , Reacción en Cadena en Tiempo Real de la Polimerasa , Receptores de Neuroquinina-1/biosíntesis , Transducción de Señal , Factor de Crecimiento Transformador beta1/biosíntesisRESUMEN
BACKGROUND: DNA methylation is one way to encode epigenetic information and plays a crucial role in regulating gene expression during embryonic development. DNA methylation marks are established by the DNA methyltransferases and, recently, a mechanism for active DNA demethylation has emerged involving the ten-eleven translocator proteins and thymine DNA glycosylase (TDG). However, so far it is not clear how these enzymes are recruited to, and regulate DNA methylation at, specific genomic loci. A number of studies imply that sequence-specific transcription factors are involved in targeting DNA methylation and demethylation processes. Oestrogen receptor beta (ERß) is a ligand-inducible transcription factor regulating gene expression in response to the female sex hormone oestrogen. Previously, we found that ERß deficiency results in changes in DNA methylation patterns at two gene promoters, implicating an involvement of ERß in DNA methylation. In this study, we set out to explore this involvement on a genome-wide level, and to investigate the underlying mechanisms of this function. RESULTS: Using reduced representation bisulfite sequencing, we compared genome-wide DNA methylation in mouse embryonic fibroblasts derived from wildtype and ERß knock-out mice, and identified around 8000 differentially methylated positions (DMPs). Validation and further characterisation of selected DMPs showed that differences in methylation correlated with changes in expression of the nearest gene. Additionally, re-introduction of ERß into the knock-out cells could reverse hypermethylation and reactivate expression of some of the genes. We also show that ERß is recruited to regions around hypermethylated DMPs. Finally, we demonstrate here that ERß interacts with TDG and that TDG binds ERß-dependently to hypermethylated DMPs. CONCLUSION: We provide evidence that ERß plays a role in regulating DNA methylation at specific genomic loci, likely as the result of its interaction with TDG at these regions. Our findings imply a novel function of ERß, beyond direct transcriptional control, in regulating DNA methylation at target genes. Further, they shed light on the question how DNA methylation is regulated at specific genomic loci by supporting a concept in which sequence-specific transcription factors can target factors that regulate DNA methylation patterns.
RESUMEN
Members of the bromodomain and extra-C terminal (BET) domain protein family and the histone deacetylase (HDAC) enzyme family regulate the expression of important oncogenes and tumor suppressor genes. Here we show that the BET inhibitor JQ1 inhibits proliferation and induces apoptosis of both triple negative and estrogen receptor positive breast cancer cells. Consistent with the critical role of histone acetylation in the regulation of gene expression, treatment with JQ1 or the HDAC inhibitor mocetinostat was associated with global changes in gene expression resulting in suppression of genes involved in cell-cycle regulation. Combining JQ1 with mocetinostat, further decreased cell viability. This synergistic effect was associated with increased suppression of genes essential for cell-cycle progression. Furthermore, we detected dramatic increase in the expression of several members of the ubiquitin-specific protease 17 (USP17) family of deubiquitinating enzymes in response to the combination treatment. Increased expression of USP17 enzymes were able to attenuate the Ras/MAPK pathway causing decrease in cell viability, while, siRNA mediated depletion of USP17 significantly decreased cytotoxicity after the combination treatment. In conclusion, our study demonstrates that co-treatment with BET inhibitors and HDAC inhibitors reduces breast cancer cell viability through induction of USP17.
Asunto(s)
Azepinas/farmacología , Neoplasias de la Mama/tratamiento farmacológico , Neoplasias de la Mama/enzimología , Endopeptidasas/biosíntesis , Inhibidores de Histona Desacetilasas/farmacología , Proteínas Nucleares/antagonistas & inhibidores , Triazoles/farmacología , Benzamidas/farmacología , Neoplasias de la Mama/genética , Proteínas de Ciclo Celular , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Sinergismo Farmacológico , Endopeptidasas/genética , Endopeptidasas/metabolismo , Inducción Enzimática/efectos de los fármacos , Femenino , Humanos , Sistema de Señalización de MAP Quinasas , Células MCF-7 , Proteínas Serina-Treonina Quinasas/antagonistas & inhibidores , Pirimidinas/farmacología , ARN Interferente Pequeño/administración & dosificación , ARN Interferente Pequeño/genética , Proteínas de Unión al ARN/antagonistas & inhibidores , Factores de Transcripción/antagonistas & inhibidores , Regulación hacia Arriba/efectos de los fármacosRESUMEN
Emerging evidence suggests that the vascular endothelial growth factor receptor 2 (VEGFR2) and protein kinase D1 (PKD1) signaling axis plays a critical role in normal and pathological angiogenesis and inflammation related processes. Despite all efforts, the currently available therapeutic interventions are limited. Prior studies have also proved that a multiple target inhibitor can be more efficient compared to a single target one. Therefore, development of novel inflammatory pathway-specific inhibitors would be of great value. To test this possibility, we screened our molecular library using recombinant kinase assays and identified the previously described compound VCC251801 with strong inhibitory effect on both VEGFR2 and PKD1. We further analyzed the effect of VCC251801 in the endothelium-derived EA.hy926 cell line and in different inflammatory cell types. In EA.hy926 cells, VCC251801 potently inhibited the intracellular activation and signaling of VEGFR2 and PKD1 which inhibition eventually resulted in diminished cell proliferation. In this model, our compound was also an efficient inhibitor of in vitro angiogenesis by interfering with endothelial cell migration and tube formation processes. Our results from functional assays in inflammatory cellular models such as neutrophils and mast cells suggested an anti-inflammatory effect of VCC251801. The neutrophil study showed that VCC251801 specifically blocked the immobilized immune-complex and the adhesion dependent TNF-α -fibrinogen stimulated neutrophil activation. Furthermore, similar results were found in mast cell degranulation assay where VCC251801 caused significant reduction of mast cell response. In summary, we described a novel function of a multiple kinase inhibitor which strongly inhibits the VEGFR2-PKD1 signaling and might be a novel inhibitor of pathological inflammatory pathways.
Asunto(s)
Proteína Quinasa C/metabolismo , Inhibidores de Proteínas Quinasas/toxicidad , Piridonas/toxicidad , Pirimidinas/toxicidad , Transducción de Señal/efectos de los fármacos , Receptor 2 de Factores de Crecimiento Endotelial Vascular/metabolismo , Línea Celular , Movimiento Celular/efectos de los fármacos , Proliferación Celular/efectos de los fármacos , Supervivencia Celular/efectos de los fármacos , Humanos , Neovascularización Patológica , Neutrófilos/efectos de los fármacos , Neutrófilos/inmunología , Neutrófilos/metabolismo , Proteína Quinasa C/antagonistas & inhibidores , Proteína Quinasa C/genética , Piridonas/química , Pirimidinas/química , Superóxidos/metabolismo , Factor A de Crecimiento Endotelial Vascular/farmacología , Receptor 2 de Factores de Crecimiento Endotelial Vascular/antagonistas & inhibidores , Receptor 2 de Factores de Crecimiento Endotelial Vascular/genéticaRESUMEN
Through their reactive oxygen species (ROS) producing function, NADPH oxidase (NOX) enzymes have been linked to several oxidative stress related diseases. In our recently published paper [1] we have already shown the NOX4 inhibitory effect of diverse, molecule sub-libraries and their biological importance. We also presented our work connected to potential anti-tumour molecules and the relationship between their biological activity and physico-chemical properties [2]. As an extension of these studies further physico-chemical and biological investigation has been carried out on a molecule group included NOX4 inhibitory chromanone compounds. Here we describe the optimization of early ADME(T) parameters determining lipophilicity, phospholipophilicity and permeability linked to structure-activity relationship. We prove that optimal lipo- and phospholipophilicty can be also determined in case of NOX4 inhibitors and a comparison will be made between the chemically similar isochromanone and chromanone molecular libraries. It will be also shown how to predict the effect of different substituents on permeability, lipo- and phospholipophilicity and also the biological differences between anti-tumour molecules and NOX4 inhibitors according to their penetration ability.
Asunto(s)
Inhibidores Enzimáticos/farmacología , NADPH Oxidasas/antagonistas & inhibidores , Células Cultivadas , Inhibidores Enzimáticos/química , Células HEK293 , Humanos , Estructura Molecular , NADPH Oxidasa 4 , NADPH Oxidasas/metabolismo , Permeabilidad/efectos de los fármacos , Relación Estructura-ActividadRESUMEN
NOX enzymes are the major contributors in many oxidative damage related diseases. Unfortunately, at present no specific NOX inhibitor is available. Here, we describe the discovery and development of novel NOX4 inhibitors. Compound libraries were tested in a cell-based assay as a primary screen, monitoring H2O2 production. Twenty-four compounds inhibited Nox4 activity with low-micromolar IC(50) values of which three were selected for further drug development.